Replies to post #2156 on Iterum Therapeutics (ITRM)

[exwannabe]

Interesting his ITRM release info about its drugs evaluation using DOOR when DOOR is not the approved endpoint evaluation. Be careful ; they are skilled at this deception.

The PR was very clear in stating DOOR is not an endpoint to be used in approvals. Further, it was about the previous trial data, and not the current trial that will determine if Sulopenam gets approved.

The point of the PR has to do with commercial value, not approvability. For antibiotics such as this, once approved it is still a marketplace battle. The PR is laying claim to marketplace value.

IMO, probably not going to be a blockbuster. But still will bring in solid cash if approved. And odds look decent.

Real issue here for investors is that they have over a year to go with the only possible news being a financing.